Literature DB >> 18425062

Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema.

E Cervera1, M Diaz-Llopis, P Udaondo, S Garcia-Delpech.   

Abstract

PURPOSE: Evaluate the efficacy of intravitreal pegaptanib sodium (Macugen) in refractory pseudophakic cystoid macular oedema (CME). DESIGN AND METHODS: Prospective, nonrandomized, interventional case series. Four eyes of four patients with refractory pseudophakic CME to pars plana vitrectomy and intravitreal bevacizumab and triamcinolone, were treated with pegaptanib sodium, with a mean follow up of 4 months. Pre- and postinfection examinations included assessment of best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study chart (ETDRS), fluorescein angiography (FA), and optical coherence tomography (OCT).
RESULTS: Visual acuity increased in all patients after intravitreal pegaptanib sodium. OCT showed improvement of the retinal thickness in the macular area.
CONCLUSION: Intravitreal pegaptanib sodium (Macugen) is a promising treatment for pseudophakic cystoid macular oedema resistant to other medical treatment strategies. However, further study is needed to assess the treatment's long term efficacy and the need for retreatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18425062     DOI: 10.1038/eye.2008.2

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  2 in total

1.  Visual perceptions induced by intravitreous injections of therapeutic agents.

Authors:  S Charalampidou; J Nolan; G O Ormonde; S Beatty
Journal:  Eye (Lond)       Date:  2011-01-28       Impact factor: 3.775

2.  EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY.

Authors:  Pilar Calvo; Antonio Ferreras; Fadwa Al Adel; Wantanee Dangboon; Michael H Brent
Journal:  Retina       Date:  2018-03       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.